ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO001

Interventions in Patient Pathways Reduce the Incidence and Complications of AKI

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Brazell, Madeline, South Tyneside NHS Foundation Trust , Gateshead, United Kingdom
  • Chernick, Jonathan Anthony, South Tyneside NHS Foundation Trust , Gateshead, United Kingdom
  • Robinson, Anna, NHS England , Newcastle, United Kingdom
  • Jones, Philip H., South Tyneside District Hospital, Co Durham, United Kingdom
  • Gaunt, Philippa L., South Tyneside NHS Foundation Trust, England, Gateshead, United Kingdom
  • Srivastava, Shalabh, City Hospitals Sunderland and South Tyneside NHS FT, Sunderland, United Kingdom
Background

We investigated the management and outcomes of patients developing AKI-3 in the South Tyneside area of the North East of England (population:153,700, census 2011). We proactively introduced interventions to aide early recognition and management of AKI. These interventions included intensive education for clinical staff in the community and hospitals, the launch of a nephrology outreach service in the South Tyneside Hospital and an online AKI health pathway tool.The study aims to scrutinize any changes in outcomes since interventions were delivered.

Methods

Methods: Data was gathered by interrogating the regional pathology database for all patients who developed AKI 3 during the periods of 1st October 16 – 31st December 2016 and subsequently from 1st October 2017 – 31st December 2017. Paediatric patients, palliative care patients and those on renal replacement therapy were excluded.

Results

We demonstrate an overall reduction of 17% in the development of AKI3 during the study period (68 vs 82 cases) additionally; we demonstrate a 29% reduction in the development of AKI-3 in hospital. The discharge to baseline creatinine ratio improved from 1.5:1 to 1.3:1. The admission to baseline creatinine ratio improved from 3.8:1 to 4.4:1. The overall mortality rates remain at 30.88% and the overall hospital stay did not change (16.1 days vs 16.2 days).

Conclusion

In conclusion, we demonstrate a significant improvement in the incidence of AKI-3 .There is early recognition of AKI and significant improvement in the renal function on discharge. We recognise that there was no improvement in overall mortality and the total number of in-patient days did not improve. Our data suggests that simple interventions at multiple levels in a patient’s pathway can lead to significant improvement in outcomes.

Comparison of Admission: Baseline and Discharge: Baseline Creatinine Ratios